Eli Lilly (LLY)

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

The biotech start-up's stock had been rising rapidly in 2025.

This drugmaker's innovation engine continues to operate at full capacity.

Lilly is reportedly shifting its 50,000 employees to Rightway, a fintech-driven pharmacy benefit manager, starting January 1.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 17.2% climb.

These three healthcare stocks are outperforming most of the sector.

A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, driven by AI hype, not earnings.

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug

The stock market, as of November 10, 2025, continues its robust rally, defying earlier recessionary fears and exhibiting significant growth across several key sectors. At the heart of this resurgence lies the technology sector, particularly those segments deeply entrenched in artificial intelligence (AI), semiconductors, and cybersecurity. This rally is not

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners upgraded the stock to Outperform from Market Perform and significantly raised its price target. 

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown in history.

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4.